Advertisement
Loading...

NeuroPace, Inc.

NPCENASDAQ
Healthcare
Medical - Devices
$15.36
$-0.43(-2.72%)
U.S. Market opens in 37h 50m

NeuroPace, Inc. Fundamental Analysis

NeuroPace, Inc. (NPCE) shows moderate financial fundamentals with a PE ratio of -23.58, profit margin of -21.67%, and ROE of -1.21%. The company generates $0.1B in annual revenue with strong year-over-year growth of 25.13%.

Key Strengths

Cash Position10.42%
PEG Ratio-0.91
Current Ratio5.38

Areas of Concern

ROE-1.21%
Operating Margin-16.84%
We analyze NPCE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -107.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-107.4/100

We analyze NPCE's fundamental strength across five key dimensions:

Efficiency Score

Weak

NPCE struggles to generate sufficient returns from assets.

ROA > 10%
-21.81%

Valuation Score

Excellent

NPCE trades at attractive valuation levels.

PE < 25
-23.58
PEG Ratio < 2
-0.91

Growth Score

Excellent

NPCE delivers strong and consistent growth momentum.

Revenue Growth > 5%
25.13%
EPS Growth > 10%
29.03%

Financial Health Score

Moderate

NPCE shows balanced financial health with some risks.

Debt/Equity < 1
4.87
Current Ratio > 1
5.38

Profitability Score

Weak

NPCE struggles to sustain strong margins.

ROE > 15%
-120.74%
Net Margin ≥ 15%
-21.67%
Positive Free Cash Flow
No

Key Financial Metrics

Is NPCE Expensive or Cheap?

P/E Ratio

NPCE trades at -23.58 times earnings. This suggests potential undervaluation.

-23.58

PEG Ratio

When adjusting for growth, NPCE's PEG of -0.91 indicates potential undervaluation.

-0.91

Price to Book

The market values NeuroPace, Inc. at 35.18 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

35.18

EV/EBITDA

Enterprise value stands at -30.81 times EBITDA. This is generally considered low.

-30.81

How Well Does NPCE Make Money?

Net Profit Margin

For every $100 in sales, NeuroPace, Inc. keeps $-21.67 as profit after all expenses.

-21.67%

Operating Margin

Core operations generate -16.84 in profit for every $100 in revenue, before interest and taxes.

-16.84%

ROE

Management delivers $-1.21 in profit for every $100 of shareholder equity.

-1.21%

ROA

NeuroPace, Inc. generates $-21.81 in profit for every $100 in assets, demonstrating efficient asset deployment.

-21.81%

Following the Money - Real Cash Generation

Operating Cash Flow

NeuroPace, Inc. generates limited operating cash flow of $-9.53M, signaling weaker underlying cash strength.

$-9.53M

Free Cash Flow

NeuroPace, Inc. generates weak or negative free cash flow of $-9.95M, restricting financial flexibility.

$-9.95M

FCF Per Share

Each share generates $-0.29 in free cash annually.

$-0.29

FCF Yield

NPCE converts -1.90% of its market value into free cash.

-1.90%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-23.58

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.91

vs 25 benchmark

P/B Ratio

Price to book value ratio

35.18

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.17

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

4.87

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.38

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.21

vs 25 benchmark

ROA

Return on assets percentage

-0.22

vs 25 benchmark

ROCE

Return on capital employed

-0.20

vs 25 benchmark

How NPCE Stacks Against Its Sector Peers

MetricNPCE ValueSector AveragePerformance
P/E Ratio-23.5828.62 Better (Cheaper)
ROE-120.74%783.00% Weak
Net Margin-21.67%-48181.00% (disorted) Weak
Debt/Equity4.870.39 Weak (High Leverage)
Current Ratio5.384.12 Strong Liquidity
ROA-21.81%-21914.00% (disorted) Weak

NPCE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NeuroPace, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-17.53%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

70.00%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

82.72%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ